https://www.selleckchem.com/pr....oducts/forskolin.htm
This will be particularly important in leading the future of SSc toward precision medicine and to promote more targeted clinical trials. The findings elucidated in EUSTAR studies have substantially improved the diagnostic and therapeutic approach to SSc in the last 15 years. Further efforts are warranted to identify early prognostic markers of the disease and stratify patients who may benefit most from vasoactive, immunosuppressive, and/or antifibrotic therapy. This will be particularly important in leading the future of SSc toward pr
Aimer
Commentaire
Partagez
